Key Points
- The Foundation has joined the Alliance for Regenerative Medicine’s (ARM) network of more than 400 organizations across 25 countries.
- ARM is the leading international advocacy organization championing the benefits of engineered cell therapies and genetic medicines.
The Foundation is among the newest members of the Alliance for Regenerative Medicine (ARM), the leading international advocacy organization championing the benefits of engineered cell therapies and genetic medicines for patients, healthcare systems, and society. According to its website, “Regenerative medicine aims to alter the current practice of medicine by treating the root causes of disease and disorders,” and it includes areas such as gene, cell, and tissue-engineered therapies.
ARM has a global membership of more than 400 organizations across 25 countries, including biotechnology companies, academic and medical research institutions, and patient groups. Its goal is to enhance research and patient access in all aspects of regenerative medicine; to do so, it assists with regulatory and reimbursement challenges, facilitates investor relations, and analyzes the state of the field.
The alliance also hosts informative webinars, workshops, and symposia on key topics and emerging research in regenerative medicine. Some of these events are open to the public while others are for members only.
“The Foundation recently launched its Gene and Cell Therapy Program to promote the use of focused ultrasound in this field, with the ultimate goal of supporting the development of clinical trials,” said Frédéric Padilla, PhD, the Foundation’s director of applied physics research who also leads the Gene Therapy Program. “We currently have eight active non-clinical projects. Given the complexity of the therapeutic approaches in this space, it is crucial for the Foundation to be part of this ecosystem through ARM, which enables us to develop partnerships and collaborations. The ARM forum is an excellent resource for learning about technological innovations and scientific advancements in the field. Additionally, the alliance provides valuable information to stay up to date on the latest clinical trials and regulatory approvals.”
The Foundation’s executive director, Bob Smith, has been involved with ARM for the past seven years and serves as the vice chair of its board of directors.
“The Foundation’s membership and participation with ARM and its broader community will add value to both of these leading organization’s efforts to advance and pioneer innovative medicines and novel treatment modalities to meaningfully improve patient’s lives,” said Bob.